1 – 20 of 22
- show: 20
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2018
-
Mark
Decline of HPV infections in Scandinavian cervical screening populations after introduction of HPV vaccination programs
2018) In Vaccine(
- Contribution to journal › Article
- 2016
-
Mark
The BRCA1-Δ11q alternative splice isoform bypasses germline mutations and promotes therapeutic resistance to PARP inhibition and cisplatin
(
- Contribution to journal › Article
-
Mark
BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers
(
- Contribution to journal › Article
-
Mark
No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer
(
- Contribution to journal › Article
-
Mark
Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus
(
- Contribution to journal › Article
- 2015
-
Mark
Germline mutation in BRCA1 or BRCA2 and ten-year survival for women diagnosed with epithelial ovarian cancer
(
- Contribution to journal › Article
- 2014
-
Mark
Targeting human papillomavirus to reduce the burden of cervical, vulvar and vaginal cancer and pre-invasive neoplasia: establishing the baseline for surveillance.
(
- Contribution to journal › Article
- 2013
-
Mark
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer
(
- Contribution to journal › Article
- 2011
-
Mark
Risk of Birth Abnormalities in the Offspring of Men With a History of Cancer: A Cohort Study Using Danish and Swedish National Registries.
(
- Contribution to journal › Article
-
Mark
Dietary factors and in situ and invasive cervical cancer risk in the European prospective investigation into cancer and nutrition study
(
- Contribution to journal › Article
-
Mark
Endogenous Sex Steroids and Risk of Cervical Carcinoma: Results from the EPIC Study
(
- Contribution to journal › Article
- 2010
-
Mark
Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial.
(
- Contribution to journal › Article
-
Mark
Impact of Human Papillomavirus (HPV)-6/11/16/18 Vaccine on All HPV-Associated Genital Diseases in Young Women.
(
- Contribution to journal › Article
- 2009
-
Mark
A Pooled Analysis of Continued Prophylactic Efficacy of Quadrivalent Human Papillomavirus (Types 6/11/16/18) Vaccine against High-grade Cervical and External Genital Lesions
(
- Contribution to journal › Article
-
Mark
The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Sexually Active Women Aged 16-26 Years
(
- Chapter in Book/Report/Conference proceeding › Paper in conference proceeding
-
Mark
Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection
(
- Contribution to journal › Article
-
Mark
The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Generally HPV-Naive Women Aged 16-26 Years
(
- Chapter in Book/Report/Conference proceeding › Paper in conference proceeding
- 2008
-
Mark
Strengthening prevention programs to eliminate cervical cancer in the Nordic countries.
(
- Contribution to journal › Scientific review
-
Mark
Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study.
(
- Contribution to journal › Article
-
Mark
HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine
(
- Contribution to journal › Article